Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU

 Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU

Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU

 Shots:

  • Moberg to receive $1.69M upfront, $56.39M milestone, royalties & supply fees based on sales of MOB-015. Bayer to get exclusive commercialization rights for MOB-015 in EU post completion of its P-III
  • The focus of the agreement is to develop MOB-015 based on Moberg’s formulation of terbinafine offering therapies & for the advancement of dermatological products for nail fungus (onychomycosis)
  • Moberg Pharma’s MOB-015 is a topical formulation of terbinafine, evaluated in P-III study in 800 patients for onychomycosis at North America and EU for 52 weeks, with its expected results in Q4’19 and Q4’20 respectively

Click here to read full press release/ article | Ref: PRNewswire  | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post